LAE122 / Laekna Therap - LARVOL DELTA

Preclinical characterization of LAE122, a novel, potent and selective WRN inhibitor for the treatment of MSI-H tumors (AACR 2025) - "LAE122 didn't have off-target liability in in vitro assays and demonstrated good tolerability in preclinical toxicology studies. In conclusion, LAE122 is a novel, potent and selective WRN inhibitor for the treatment of MSI-H tumors."

IO biomarker • MSI-H • Preclinical • Endometrial Cancer • Microsatellite Instability • Oncology • Ovarian Cancer • Solid Tumor • MSI • WRN